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The eﬀ ect of social deprivation on clinical outcomes and the 
use of treatments in the UK cystic ﬁ brosis population: 
a longitudinal study
David C Taylor-Robinson, Rosalind L Smyth, Peter J Diggle, Margaret Whitehead
Summary
Background Poorer socioeconomic circumstances have been linked with worse outcomes in cystic ﬁ brosis. 
We assessed whether a relation exists between social deprivation and individual’s clinical and health-care outcomes. 
Methods We did a longitudinal registry study of the UK cystic ﬁ brosis population younger than 40 years (8055 people 
with 49 337 observations for weight, the most commonly collected outcome, between Jan 1, 1996, and Dec 31, 2009). We 
assessed data for weight, height, body-mass index, percent predicted forced expiratory volume in 1 s (%FEV1), risk of 
Pseudomonas aeruginosa colonisation, and the use of major cystic ﬁ brosis treatment modalities. We used mixed eﬀ ects 
models to assess the association between small-area deprivation and clinical and health-care outcomes, adjusting for 
clinically important covariates. We give continuous outcomes as mean diﬀ erences, and binary outcomes as odds ratios, 
comparing extremes of deprivation quintile.
Findings Compared with the least deprived areas, children from the most deprived areas weighed less (standard 
deviation [SD] score –0·28, 95% CI –0·38 to –0·18), were shorter (–0·31, –0·40 to –0·21, and had a lower body-
mass index (–0·13, –0·22 to –0·04), were more likely to have chronic P aeruginosa infection (odds ratio 1·89, 
95% CI 1·34 to 2·66), and have a lower %FEV1 (–4·12 percentage points, 95% CI –5·01 to –3·19). These inequalities 
were apparent very early in life and did not widen thereafter. On a population level, after adjustment for disease 
severity, children in the most deprived quintile were more likely to receive intravenous antibiotics (odds ratio 2·52, 
95% CI 1·92 to 3·17) and nutritional treatments (1·78, 1·44 to 2·20) compared with individuals in the least 
deprived quintile. Patients from the most disadvantaged areas were less likely to receive DNase or inhaled 
antibiotic treatment.
Interpretation In the UK, children with cystic ﬁ brosis from more disadvantaged areas have worse growth and lung 
function compared with children from more aﬄ  uent areas, but these inequalities do not widen with advancing age. 
Clinicians consider deprivation status, as well as disease status, when making decisions about treatments, and this 
might mitigate some eﬀ ects of social disadvantage.
Funding Medical Research Council (UK).
Introduction
Cystic ﬁ brosis is the most common life-limiting 
inherited disease in white populations, with most 
patients dying prematurely from respiratory failure. 
Children with cystic ﬁ brosis in the UK and in other 
high-income countries are usually diagnosed in the ﬁ rst 
year of their life,1 and subsequently need intensive 
support from family and health-care services.
Cystic ﬁ brosis is of particular interest in the study of 
health inequalities, because it is a genetic disease and 
there is no social gradient in incidence of the disorder—it 
aﬀ ects all socioeconomic groups equally (appendix). 
Inequalities can develop, however, in the outcomes 
experienced by people with the disease. People with cystic 
ﬁ brosis from socioeconomically disadvantaged back-
grounds, for example, die younger than do those in more 
advantaged social positions in the UK and the USA.2–5 
Between 1986 to 1994, the adjusted risk of death was 
3·65 times higher in patients with cystic ﬁ brosis in the 
USA with Medicaid cover (taken as an indicator of poverty) 
than it was in those without Medicaid cover.2 In England 
and Wales, between 1959 and 2008, Barr and Fogarty 
recorded an increased risk of dying later, at an age above 
the median of all deaths due to cystic ﬁ brosis, in more 
advantaged social classes, a pattern that has persisted for 
more than four decades.5 As with other chronic diseases, 
this social patterning of survival in cystic ﬁ brosis implies 
that social and environmental factors aﬀ ect outcomes.6,7 
Inequalities in access to specialist health care might also 
be important, because in many health-care systems 
provision and use of services decreases with patients’ 
income,8,9 the so-called inverse care law.10
To gain a better understanding of when and how 
inequalities in outcomes develop in cystic ﬁ brosis, we 
undertook a longitudinal registry study to explore the 
eﬀ ect of deprivation on growth, nutrition, lung function, 
risk of Pseudomonas aeruginosa colonisation, and the use 
of major cystic ﬁ brosis treatment modalities in a UK-
wide population cohort, in the context of a universal 
health-care system, free at the point of use.
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Methods
Study design and data sources
We undertook a longitudinal retrospective cohort study of 
individuals in the UK cystic ﬁ brosis registry who were 
younger than 40 years at last follow-up, with at least one 
outcome measurement and a valid postcode between 
Jan 1, 1996, and Dec 31, 2009. The UK cystic ﬁ brosis 
registry is supported and coordinated by the UK Cystic 
Fibrosis Trust.11,12 The UK cystic ﬁ brosis registry is 
maintained to a high standard of data quality, and is 
estimated to include nearly all people thought to have 
cystic ﬁ brosis in the UK population13 and is therefore 
ideally suited to the study of outcomes and treatments 
across the whole socioeconomic spectrum in the UK 
(appendix).
NHS research ethics approval (Huntingdon Research 
Ethics Committee 07/Q0104/2) was granted for the 
collection of data into the UK database. The Cystic 
Fibrosis Trust database committee approved the use of 
anonymised data in this study.
Primary outcome and covariates
The primary clinical outcomes were weight, height, 
body-mass index (BMI), percent predicted forced expiratory 
volume in 1 s (%FEV1), and prevalence of P aeruginosa 
colonisation. Anthropometric values were converted into 
standard deviation [SD] scores using the UK reference 
population.14 The primary health-care outcomes were use 
of treatments in the previous year (yes or no): intravenous 
antibiotics, supplemental nutritional support, DNase, or 
inhaled antibiotic treat ment. Conditional on the use of 
intravenous treatment, we also used the log total number 
of days on intravenous treatment as a secondary outcome.
The primary exposure measure was a small-area-
based measure of deprivation of area of residence. 
Postcodes were used to derive Index of Multiple 
Deprivation scores for the constituent UK countries15 
and each person was allocated to a deprivation score on 
the basis of the ﬁ rst recorded postcode on entry to the 
dataset. Other baseline covariates in the analysis were: 
sex, genotype coded as the number of delta F508 alleles 
(0, 1, or 2), year of birth, screening status (diagnosis by 
neonatal screening or otherwise), and ethnic origin 
(white or other). Time-varying covariates were age, 
presence of cystic ﬁ brosis related diabetes (CFRD), and 
presence of pancreatic insuﬃ  ciency (ie, whether or not 
an individual used pancreatic enzyme supplementation). 
In our health-care use analyses, we adjusted for disease 
severity on the basis of current %FEV1, P aeruginosa 
status, and BMI SD score.
Statistical analysis
Full details are provided in the supplementary appendix. 
Brieﬂ y, we ﬁ tted separate longitudinal models in the 
paediatric (<18 years) and adult (18–40 years) age ranges. 
We then approximated time-trends using linear func tions 
(eg, for %FEV1), piecewise or broken-stick functions 
(weight, BMI), or quadratics (eg, any intravenous treat-
ment), as appropriate. For instance, population 
weight SD score increased to about age 3 years, and then 
decreased subsequently (appendix). The modelling ap-
proach involved ﬁ rst ﬁ tting a model adjusted for age and 
the baseline covariates deﬁ ned above, and then testing for 
the signiﬁ cance of adding deprivation. Finally, the time-
varying covariates were added to the model, to assess 
whether the deprivation coeﬃ  cient was modiﬁ ed. We 
1 (least 
deprived)
2 3 4 5 (most 
deprived)
All p value
Number of patients 1537 (19%) 1563 (19%) 1591 (20%) 1736 (22%) 1628 (20%) 8055 0·0018 
Observations (for weight SD score) 9500 (19%) 9706 (20%) 9708 (20%) 10 550 (21%) 9873 (20%) 49 337 <0·0001
Female sex 712 (46%) 726 (46%) 728 (46%) 825 (48%) 773 (48%) 3764 (47%) 0·38
Age in days at diagnosis (IQR) 121 (30–731) 121 (30–670) 113 (30–730) 109 (30–728) 120 (30–730) 120 (30–730) 0·39
Number of delta F508 alleles
2 824 (54%) 827 (53%) 822 (52%) 907 (52%) 779 (48%) 4159 (52%) 0·0022
1 543 (35%) 556 (36%) 560 (35%) 609 (35%) 594 (37%) 2862 (36%) 0·63
0 170 (11%) 180 (12%) 209 (13%) 220 (13%) 255 (16%) 1034 (13%) <0·0001 
Non-white 31 (2%) 31 (2%) 52 (3%) 73 (4%) 120 (7%) 307 (4%) <0·0001
Screened 233 (15%) 272 (17%) 245 (15%) 282 (16%) 277 (17%) 1309 (16%) 0·39
Birth cohort 
1957 to 1966 62 (4%) 49 (3%) 64 (4%) 51 (3%) 35 (2%) 261 (3%) <0·0045
1967 to 1976 157 (10%) 172 (11%) 182 (11%) 171 (10%) 153 (9%) 835 (10%) 0·23
1977 to 1986 329 (21%) 384 (25%) 369 (23%) 426 (25%) 396 (24%) 1904 (24%) 0·09
1987 to 1996 496 (32%) 478 (31%) 489 (31%) 535 (31%) 530 (33%) 2528 (31%) 0·82
1997 to 2006 396 (26%) 393 (25%) 396 (25%) 427 (25%) 410 (25%) 2022 (25%) 0·62
2007 to <2010 97 (6%) 87 (6%) 91 (6%) 126 (7%) 104 (6%) 505 (6%) 0·32
Data are n (%) unless otherwise stated. 
Table 1: Unadjusted characteristics of study population by deprivation quintile (UK cystic ﬁ brosis registry 1996 to 2009)
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estimated all model parameters by maximum likelihood, 
using linear or generalised linear mixed eﬀ ects models.16 
We used generalised likelihood ratio statistics to compare 
nested models, and Wald statistics to test hypotheses about 
model parameters. We used R (version 2.9.2) for all 
statistical analyses.
Role of the funding source
The study sponsor had no role in the design, collection, 
analysis, or interpretation of the data, in the writing of 
the report, or in the decision to submit the article for 
publication. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The ﬁ nal dataset for weight SD scores, the most 
commonly collected outcome, contained information 
collected at 49 337 annual reviews for 8055 patients 
between Jan 1, 1996 and Dec 31, 2009, in the UK (table 1 
and appendix). 5324 (66%) individuals had ﬁ ve or more 
follow-up measures (appendix), with a total of 
48 425 person-years of follow-up. We recorded no relation 
between sex ratios, birth cohort, neonatal screening and 
deprivation status (table 1), or number of incident cases, 
and age at diagnosis and deprivation status (appendix). 
We recorded a slight trend towards fewer heterozygote 
delta F508 carriers (p=0·0022), more people with no delta 
F508 genes (p<0·0001), and a greater proportion of non-
white patients with increasing level of deprivation 
(p<0·0001). Compared with the UK reference population, 
the population of patients with cystic ﬁ brosis weighed 
less (SD score –0·37, 95% CI –0·43 to –0·35 [35th centile]), 
were shorter (–0·50, –0·53 to –0·47 [30th centile]), and 
had a lower BMI (–0·08, –0·11 to –0·06 [46th centile]; in 
models ignoring time trends).
Weight SD scores increased from diagnosis up to about 
the age of 3 years, decreasing thereafter (appendix). After 
adjustment for baseline factors, at diagnosis, the weight 
of children in the most deprived quintile was lower than 
that of children in the least deprived quintile (weight SD 
score –0·54, 95% CI –0·73 to –0·34). The deprivation gap 
diminished with increasing age up to age 3 years, and 
from then on remained constant (table 2 and appendix). 
A higher weight SD score was associated with male sex, 
screened patients, heterozygotes for delta F508, and 
white patients (appendix). In adults, adjusted weight-for-
age was lower in more deprived groups (table 2).
The average height of individuals in the most deprived 
quintile compared with the least deprived quintile was 
also about a third of an SD score shorter in the adjusted 
analysis, a diﬀ erence that remained constant across all 
ages (table 2 and appendix). In patients younger than 
18 years, a bigger height SD score was statistically 
signiﬁ cantly associated with male sex and screened 
patients, and statistically signiﬁ cantly increased in white 
patients with age (appendix).
We modelled BMI SD score much like we modelled 
weight SD score, with a split-line at age 3 years. In the 
paediatric age range, there was a deprivation gap (with 
lower scores in the most derived groups) of –0·13 
(–0·22 to –0·04; table 2). Higher BMI was associated with 
male sex in the paediatric age range (individuals ages 
0–18 years), and had a steeper rate of decline in delta F508 
homozygotes after the age of 3 years (appendix). In the 
adult age range, we recorded no association between BMI 
SD score and deprivation status (–0·12, –0·25 to 0·01; 
ﬁ gure 1 and table 2).
Addition of the time-varying covariates did not 
substantially alter the deprivation eﬀ ects for growth 
outcomes, and the esti mates were consistent with a 
monotonic dose-response relation between deprivation 
and both weight and height.
In the ﬁ nal model for %FEV1, we detected a diﬀ erence 
of –4·1 percentage points (–5·0 to –3·1) when comparing 
children (<18 years) in the most deprived quintile with 
those in the least deprived quintile (a diﬀ erence that was 
apparent from as soon as %FEV1 can be measured at about 
5 years of age), but there was no evidence of an increased 
rate of decline in children from more deprived quintiles. 
Higher %FEV1 was associated with male sex, screened 
patients, heterozygote delta F508 status, white patients, no 
CFRD, no P aeruginosa colonisation, and higher BMI 
(ﬁ gure 2 and appendix). Further adjustment for 
Burkholderia cenocepacia status and care centre did not 
change the deprivation eﬀ ect on %FEV1 (appendix). The 
addition of BMI SD score to the model reduced the %FEV1 
deprivation gap to –3·5 percentage points (–5·2 to –1·8). 
There was no statistically signiﬁ cant asso ciation between 
%FEV1 and social deprivation in the adult age range 
(table 2). The cross-sectional proportion of people with 
chronic P aeruginosa infection increased steadily with age 
Patients younger than 
18 years
Patients aged 
18 years to <40 years
Clinical outcomes*
FEV1 (percentage points [95% CI]) –4·12 (–5·01 to –3·19) –1·6 (–4·41 to 1·25)
Weight-for-age (SD score [95% CI]) –0·28 (–0·38 to –0·18) –0·31 (–0·46 to –0·16)
Height-for-age (SD score [95% CI]) –0·31 (–0·40 to –0·21) –0·31 (–0·43 to –0·19)
BMI-for-age (SD score [95% CI]) –0·13 (–0·22 to –0·04) –0·12 (–0·25 to 0·01)
Pseudomonas aeruginosa colonisation (OR [95% CI]) 1·89 (1·34 to 2·66) 1·78 (1·26 to 2·51)
Treatments
Any intravenous treatment (OR [95% CI])† 2·52 (1·92 to 3·17) 1·89 (1·51 to 2·38)
Total intravenous days per year (% change [95% CI])† 15·9 (8·2 to 24) 10·6 (2·5 to 19·2)
Supplemental feeding (OR [95% CI])‡ 1·78 (1·42 to 2·2) 2·38 (1·69 to 3·36)
DNase treatment (OR [95% CI])† 0·40 (0·21 to 0·72) 0·37 (0·26 to 0·52)
Use of inhaled antibiotics (OR [95% CI])† 0·66 (0·47 to 0·93) 0·40 (0·31 to 0·5)
All estimates compare the most deprived quintile to the least deprived (reference) quintile. *The outcomes are from 
separate longitudinal models adjusted for time trends, sex, genotype, screening status, and ethnic origin. †Adjusted for 
time trends, sex, genotype, screening status, (FEV1), and Pseudomonas aeruginosa colonisation status. ‡Adjusted for time 
trends, sex, genotype, screening status, and body mass index (BMI) SD score. 
Table 2: Summary of adjusted eﬀ ects of deprivation on clinical outcomes and use of treatments in 
patients with cystic ﬁ brosis in the UK
Articles
124 www.thelancet.com/respiratory   Vol 1   April 2013
to about 60% by the age of 20 years, and was more common 
in the most deprived quintile, with an odds ratio (OR) of 
1·9 (95% CI 1·3 to 2·7) in the adjusted paediatric analysis 
for the most deprived quintile (table 2 and ﬁ gure 2). An 
increased likelihood of P aeruginosa colonisation was 
associated with female sex, homozygote delta F508 status, 
CFRD, pancreatic in suﬃ  ciency, and lower %FEV1, but 
adjustment for these factors did not substantially alter the 
deprivation eﬀ ect (data not shown). The estimates were 
consistent with a monotonic dose-response relation 
between deprivation and %FEV1 (appendix) and risk of 
P aeruginosa colonisation (data not shown).
The use of any intravenous treatment, after adjustment 
for disease severity, was more than twice as common in 
the most deprived children cohort compared with the least 
deprived children cohort (table 2), and this deprivation 
diﬀ erence was also present in adults (table 2 and ﬁ gure 3). 
Further adjustment for care centre did not change this 
eﬀ ect. Conditional on receipt of intra venous treatment, 
and after adjustment for disease severity, people in the 
most deprived quintile had more days of intravenous 
treatment in both the paediatric and adult age range 
(table 2). We analysed the receipt of hospital and at-home 
intravenous treatment separately and noted that the higher 
prevalence of any intravenous treatment seen in the most 
deprived quintile was almost entirely due to delivery of 
such treatment in hospital rather than home (ﬁ gure 3). For 
intravenous treatment at home, the association with social 
deprivation was much less strong, and, in the cross-
sectional analysis, at-home intravenous treatment was 
more common in the least deprived quintile compared 
with the most deprived quintile in patients between the 
ages of 10 years and 27 years (ﬁ gure 3). Prevalence of any 
supplemental feeding therapy in the previous year was 
more common in the most deprived quintile, compared to 
the least, across the entire age range from age 0 years to 
age 40 years (OR 1·78, 95% CI 1·42 to 2·2, adjusted for 
baseline variables, P aeruginosa infection status, and BMI, 
in the 5–18 age group, ﬁ gure 3).
We detected no statistically signiﬁ cant association 
between DNase use and deprivation in the paediatric age 
range before we adjusted for disease severity. After ad-
justment for disease severity, treatment was less likely in 
the most deprived quintile, in both children and adults, 
although the association with deprivation was stronger in 
adults. We saw a similar pattern for inhaled antibiotic 
treat ment (table 2 and ﬁ gure 3). The estimates were con-
sist ent with a monotonic dose-response relation between 
socioeconomic status and treatment outcomes (appendix).
Discussion
Our ﬁ ndings show that children with cystic ﬁ brosis from 
the most disadvantaged areas in the UK have lower weight, 
height, and BMI in the ﬁ rst years of life after diagnosis, are 
more likely to have chronic P aeruginosa infection, and 
have a lower %FEV1 than do children in the least 
disadvantaged areas. These social inequalities persist into 
adulthood but do not widen.
Our ﬁ ndings suggest evidence of positive discrim-
ination, or so-called pro-poor bias, in the provision of some 
key treatments, on the basis of socioeconomic circum-
stances. We show that in the NHS, compared with children 
with cystic ﬁ brosis in the least dis advantaged areas, 
children with cystic ﬁ brosis from the most disadvantaged 
areas are about twice as likely, after adjustment for disease 
severity, to receive intravenous antibiotics (speciﬁ cally in 
hospital) and nutritional support. Our ﬁ ndings also show 
some apparent bias in favour of wealthier populations, a 
so-called pro-rich bias, in two other treatments, DNase and 
inhaled antibiotics, with patients from the most aﬄ  uent 
areas being more likely to receive these treatments after 
adjustment for disease severity.
Key strengths of this study include the population-wide 
coverage of the UK cystic ﬁ brosis registry, the high quality 
of the data, and the longitudinal analysis. However, our 
study does have limitations. First, it relies on 
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Figure 1: Comparison of anthropometric outcomes, by age and socioeconomic status
Mean cross-sectional (A) weight, (B) height, and (C) body-mass index (BMI).
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retrospective, routinely collected data and we used a 
standard measure of deprivation of area of residence. 
Each small area contains about 1500 people, and, in this 
respect, the Index of Multiple Deprivation scores allowed 
much ﬁ ner resolution than US analyses3,17,18 that have 
used ZIP-code-linked income data, because every ZIP 
code contains about 30 000 people (panel).19 There is 
always the possibility of ecological fallacy (whereby 
inferences made at the group level do not apply to the 
individual), but this possibility is unlikely in view of the 
fact that similar associations have been seen in the US 
studies that use both area and individual measures of 
socioeconomic status.3,17,18 Second, we had valid postcodes 
for only 90% of the sample, although our sample size 
was large, with no pronounced gradient in the proportion 
of patients by deprivation quintile. The excluded 
population—those with no valid postcode—were largely 
older birth cohorts, owing to the improved collection of 
postcodes by clinical staﬀ  over time, but we do not believe 
that this has biased the associations detected in our 
analysis (appendix). Third, there is a strong cohort eﬀ ect 
in cystic ﬁ brosis and, with datasets of this type, age and 
cohort eﬀ ects confound one another, and cannot be 
completely separated.20 We have adjusted for both in our 
analysis, to estimate the adjusted eﬀ ect on deprivation.
Overall, the UK cystic ﬁ brosis population is under-
weight and shorter compared with the UK reference 
population, by about a third of an SD score. Deprivation 
roughly doubles this eﬀ ect, lowering the SD score by 
another third. How much of the eﬀ ect of socioeconomic 
status on growth outcomes is speciﬁ c to cystic ﬁ brosis, 
and how much is attributable to socioeconomic status 
eﬀ ects in the general population is unclear. Comparable 
data in contemporary representative cohorts in the UK is 
absent, but the age-related changes in growth in the 
general population are characterised by increasing 
obesity in childhood from the age of 4 years onwards, 
with higher BMI in the more deprived populations,21,22 
ﬁ ndings which contrast with the patterns seen in our 
study. The projected weight diﬀ erence at intercept in our 
study (–0·54) by socioeconomic status is also larger than 
those in other recent studies,23,24 but direct comparison 
between these studies and ours is complicated by the use 
of diﬀ erent socioeconomic status measures. We speculate 
that having cystic ﬁ brosis is likely to amplify the eﬀ ects 
of socioeconomic status on nutritional status at birth and 
in the ﬁ rst few years of an individual’s life.
The inequality in weight is greatest at around the time 
of diagnosis, and becomes narrower over the ﬁ rst 
3 years of life. This is an important ﬁ nding, because a 
widening of inequalities over time is often the norm.7,25,26 
These ﬁ ndings suggest that extending the period of 
diﬀ erential weight gain for as long as possible might 
reduce in equalities, further lending support to neonatal 
screening programmes to enable early diagnosis and 
treatment.27 We speculate that by extending this period 
of catch-up for as long as possible by early diagnosis (ie, 
screening) we might see an attenuation of the 
deprivation eﬀ ect over time. In this study, we detected 
no diﬀ erence in the age at diagnosis by deprivation, but 
screening was associated with increased weight and 
height and improved lung function in children. 
Furthermore, our ﬁ nding that the prevalence of 
supplemental feeding treatment was higher, after 
adjusting for disease severity, in the most disadvantaged 
patients suggests that NHS professionals are actively 
engaged in trying to boost the nutrition of poorer 
patients, recognising their health disadvantage.
Figure 2: Comparison of respiratory outcomes, by age and socioeconomic status
Mean cross-sectional (A) FEV1 and (B) Pseudomonas aeruginosa colonisation prevalence. 
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The socioeconomic gradient in lung function, evident 
as soon as it can be routinely measured at the age of 
5 years, points to the crucial role of environmental and 
health-care factors operating in the early years of life to 
produce inequalities. It further reinforces the need for 
early diagnosis and action to prevent adverse con-
sequences for children with cystic ﬁ brosis living in 
disadvantaged circumstances. In Schechter and col-
leagues’ cross-sectional study of US data,2 inequalities in 
%FEV1 by Medicaid status widened slightly from age 
5 years to age 20 years. The magnitude of the inequalities 
in lung function at the age of 5 years seen in Schechter’s 
study was larger (about a 9% diﬀ erence) than in our UK 
study (4%), as was the magnitude of inequalities in lung 
function seen in O’Connor and colleagues’ US study,3 
which showed a diﬀ erence of 5·5% between the most 
and least deprived quintiles. Methodological diﬀ erences 
between the studies, however, make a direct comparison 
between these UK and US ﬁ ndings inappropriate. This 
study is the ﬁ rst to examine the relation between 
deprivation and %FEV1 in a population-level, adult 
cohort. We did not detect an association, despite the 
higher prevalence of P aeruginosa. We speculate that this 
ﬁ nding might relate to the complication of progressive 
drop-out in older patients, and the insensitivity of %FEV1 
as an outcome measure in adults.20
The increased prevalence of chronic P aeruginosa 
infection in patients from more deprived areas, after 
adjusting for %FEV1, is a new ﬁ nding in a population-level 
cohort. In Schechter and colleagues’ study,2 Medicaid-
insured patients were more likely to have P aeruginosa 
infection than were patients who were not eligible for 
Medicaid insurance, but when adjusted for %FEV1 there 
was no statistically signiﬁ cant diﬀ erence—another US 
cohort study did not detect an association either.28 
Previously identiﬁ ed risk factors for P aeruginosa 
acquisition, which is associated with worse lung func tion, 
include female sex and genotype (both associations shown 
in this study), and exposure to other patients with 
P aeruginosa colonisation.29 Our ﬁ nding that more deprived 
Figure 3: Comparison of treatment methods, by age and socioeconomic status
Proportion of patients who received (A) any intravenous antibiotic treatment, (B) home intravenous antibiotic treatment, (C) hospital intravenous antibiotic 
treatment, (D) supplemental feeding, (E) DNase, and (F) inhaled antibiotics.
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groups are more likely to receive intravenous treatment in 
hospital might result in more deprived patients having 
greater exposure to other patients with chronic 
P aeruginosa, therefore increasing their risk of infection.
We saw substantial socioeconomic diﬀ erences in the 
reported use of key cystic ﬁ brosis treatments in two 
contrasting ways. First, children from the most deprived 
quintile were about twice as likely to receive hospital 
intravenous antibiotic treatment and nutritional support, 
after adjustment for disease severity, compared with those 
from the least deprived quintile. We can speculate, from 
our knowledge of UK cystic ﬁ brosis services, that clinicians 
in the NHS are more likely to bring children from more 
deprived areas into hospital for intravenous treatment 
because of concerns about the diﬃ  culties in delivering 
treatments in their homes. Conversely, children living in 
more aﬄ  uent areas might receive intravenous treatment 
at home because of judgments about the adequacy of 
support and adherence to treatment in their home or 
because of their families’ wish to avoid disruption to 
schooling and family life. This equitable model of care, 
with positive discrimination for socially disadvantaged 
children and adults with cystic ﬁ brosis, is an uncommon 
ﬁ nding in health systems, when access, particularly to 
secondary care for adults, often decreases with increasing 
deprivation, after ad justing for diﬀ erential need.8,30 While 
several studies have seen use of health services by level of 
deprivation to be more equal in relation to children than 
adults,31 we have detected evidence in children with cystic 
ﬁ brosis that goes even further with a pro-poor bias in the 
NHS for speciﬁ c treatments. Coupled with our ﬁ ndings of 
inequalities in outcomes by deprivation, which do not 
widen over time, we speculate that the treatment decisions 
being made by clinicians might mitigate some eﬀ ects of 
social dis advantage. This provides encourage ment that 
there are interventions that health services can make to 
reduce the adverse eﬀ ects of deprivation on chronic 
disorders such as cystic ﬁ brosis. In the USA, with use of 
ZIP-code-linked income of an area as the socio economic 
indicator, there was no gradient in intravenous treatment 
use in children younger than 12 years, but in young people 
aged 13–18 years, those living in more aﬄ  uent areas were 
more likely to be treated (13·8% in the lowest income 
category compared with 19·2% in the highest).18
Our second, and contrasting, set of ﬁ ndings on cystic 
ﬁ brosis treatments, however, point to an apparent pro-
rich bias in two other treatments, which were more 
evident in adults than in children: more aﬄ  uent adults 
in the UK were more likely to receive DNase and inhaled 
antibiotics than were their more disadvantaged counter-
parts. DNase is an expensive treatment to reduce viscosity 
of sputum and to aid sputum expectoration, and some 
evidence exists that it prevents decrease in %FEV1.32 
These treatments, although expensive, are free of charge 
to all patients in the NHS. One possibility for the social 
disparity in access to them is that they are both home-
based treatments, requiring regular and long-term 
administration. Socially disadvantaged patients with 
cystic ﬁ brosis are less likely to adhere to treatments,29 and 
if they report poor adherence, clinicians might be less 
likely to prescribe these drugs because they are unlikely 
to be as eﬀ ective if taken inconsistently. Evidence from 
the USA shows no diﬀ erence in use of DNase in children 
by area income quintile, but Medicaid-insured children 
(ie, those receiving free or subsidised care) were more 
likely to receive DNase than were children who were not 
eligible for Medicaid insurance.17
Further research is needed to clarify which elements 
of the cystic ﬁ brosis care model might contribute to a 
reduction in the adverse outcomes associated with 
deprivation. A cause for concern is the fact that the most 
disadvantaged families have a higher burden of treatment, 
in terms of time spent in hospital, which increases 
disruption to school and family life. Furthermore, the link 
with P aeruginosa colonisation requires further 
investigation. Higher socioeconomic status, as measured 
by parental education status, is associated with improved 
adherence to treatment in cystic ﬁ brosis,29 and further 
research is needed to investigate the processes that lead to 
these diﬀ erences. Systems to support the provision of 
intra venous treatment at home for more deprived groups 
in the UK should be explored.
Diﬀ erences in access to health care cannot explain the 
diﬀ erences in weight and height, by socioeconomic 
status, that are evident at the time of diagnosis, and are 
Panel: Research in context
Systematic review
We searched PubMed with the terms “(cystic ﬁ brosis) and (inequality OR equity OR inequity 
OR socioeconomic OR disadvantage OR vulnerable OR poverty OR social class OR disparity)” 
to identify relevant studies on the eﬀ ect of socioeconomic status on outcomes and 
treatment in people with cystic ﬁ brosis. We applied no date or language restrictions. We 
identiﬁ ed a review that summarises all studies,29 much of which were done in the USA, where 
the health-care system is diﬀ erent to that in the UK. People with cystic ﬁ brosis from 
socioeconomically disadvantaged backgrounds die younger than do those in more 
advantaged social positions in the UK5 and the USA.2 The key challenge is to understand how 
and when these inequalities develop, and to understand how the health-care system in the 
UK can mitigate or perpetuate these eﬀ ects to identify promising options for intervention.
Interpretation
This study has identiﬁ ed important longitudinal diﬀ erences in weight, height, body-mass 
index, forced expiratory volume in 1 s, and risk of Pseudomonas aeruginosa colonisation by 
deprivation in people with cystic ﬁ brosis in the UK, which start early in life, but do not 
increase over time. We detected socioeconomic diﬀ erences in the reported use of key 
treatments in the UK. People from more deprived areas are about twice as likely to receive 
in-hospital intravenous antibiotic treatment and nutritional support, but less likely to 
receive DNase and inhaled antibiotics. Interventions to reduce inequalities in outcomes in 
cystic ﬁ brosis need to be focused in the antenatal period and the early years of life. Such 
interventions include smoking prevention and public health initiatives to address 
inequalities in maternal and child health. Further research is needed to clarify which 
elements of the cystic ﬁ brosis care model in the UK might contribute to a reduction in the 
adverse outcomes associated with deprivation, and to investigate identiﬁ ed diﬀ erences in 
access to inhaled treatments.
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unlikely to explain the gradient in lung function evident 
at around the age of 5 years. The UK cystic ﬁ brosis 
registry does not capture data about smoking in the home 
and these early eﬀ ects might be associated with the 
known diﬀ erences in smoking prevalence by socio-
economic status in the UK.33 The eﬀ ect of socioeconomic 
status on growth in utero and in the early years of life in 
people with cystic ﬁ brosis, might be mediated, at least in 
part, by maternal smoking, thus aﬀ ecting subsequent 
outcomes and ultimately survival.
Future studies should focus on the assessment of 
interventions, such as the reduction of exposure to 
environmental tobacco smoke,34 which might mitigate the 
eﬀ ects of deprivation during the critical early years of life, 
and on the identiﬁ cation of aspects of health-care provision 
in cystic ﬁ brosis that would help overcome the extra burden 
of adverse consequences of cystic ﬁ brosis faced by patients 
living in economically-disadvantaged circumstances.
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